LRRC20: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker for Cancer

Target Name: LRRC20

NCBI ID: G55222

LRRC20

LRRC20: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker for Cancer

LRRC20 (Long non-coding RNA-rich cluster 20) is a non-coding RNA molecule that has been identified as a potential drug target in various diseases, including cancer. LRRC20 is a member of the LRNA family, which is known for its ability to interact with proteins and regulate gene expression.

The LRRC20 molecule has a unique structure that consists of 21 non-coding RNA modules clustered together in a hierarchical organization. These modules are characterized by a long non-coding RNA sequence that is repeated multiple times, as well as short coding RNA sequences that are unique to each module.

LRRC20 has been shown to play a role in various cellular processes, including cell growth, differentiation, and transcriptional regulation. For example, studies have shown that LRRC20 can promote the growth of cancer cells and contribute to their survival. Additionally, LRRC20 has been shown to regulate cell proliferation and induce cell apoptosis, which is a natural process that helps remove damaged or unneeded cells from the body.

As a potential drug target, LRRC20 is being targeted for its ability to promote cancer cell growth and survival. Researchers are interested in developing small molecules or other compounds that can inhibit the activity of LRRC20 and prevent cancer cells from developing. This approach is still in the early stages of research, but it holds great promise as a new treatment option for various diseases.

LRRC20 is also being studied as a biomarker for cancer diagnosis and treatment. The expression of LRRC20 has been shown to be altered in various types of cancer, including breast, lung, and ovarian cancer. Additionally, studies have shown that LRRC20 can be used as a biomarker for cancer recurrence after surgery or chemotherapy.

In conclusion, LRRC20 is a non-coding RNA molecule that has been identified as a potential drug target for various diseases, including cancer. Its unique structure and various cellular functions make it an attractive target for small molecules and other compounds that can inhibit its activity. As a biomarker for cancer diagnosis and treatment, LRRC20 is also a promising tool for the development of new therapies for various diseases. Further research is needed to fully understand the role of LRRC20 in disease and to develop effective treatments.

Protein Name: Leucine Rich Repeat Containing 20

The "LRRC20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets